KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer

Background: We evaluated KRAS ( mKRAS (mutant KRAS )) and BRAF ( mBRAF (mutant BRAF )) mutations to determine their prognostic potential in assessing patients with colorectal cancer (CRC) for lung metastasectomy. Methods: Data were reviewed from 180 patients with a diagnosis of CRC who underwent a l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2015-02, Vol.112 (4), p.720-728
Hauptverfasser:	Renaud, S, Romain, B, Falcoz, P-E, Olland, A, Santelmo, N, Brigand, C, Rohr, S, Guenot, D, Massard, G
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/737 692/53/2422 692/699/67/1504/1885 692/700/565/545 Adenocarcinoma - diagnosis Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma - surgery Aged Biomarkers Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Colorectal cancer Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery Drug Resistance Epidemiology Female Humans Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - secondary Lung Neoplasms - surgery Male Medical prognosis Metastasectomy Metastasis Middle Aged Molecular Diagnostics Molecular Medicine Mutation Oncology Ostomy Prognosis Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Retrospective Studies Risk factors Sarcoma Surgeons Thoracic surgery Tomography Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: We evaluated KRAS ( mKRAS (mutant KRAS )) and BRAF ( mBRAF (mutant BRAF )) mutations to determine their prognostic potential in assessing patients with colorectal cancer (CRC) for lung metastasectomy. Methods: Data were reviewed from 180 patients with a diagnosis of CRC who underwent a lung metastasectomy between January 1998 and December 2011. Results: Molecular analysis revealed mKRAS in 93 patients (51.7%), mBRAF in 19 patients (10.6%). In univariate analyses, overall survival (OS) was influenced by thoracic nodal status (median OS: 98 months for pN−, 27 months for pN+, P
ISSN:	0007-0920 1532-1827
DOI:	10.1038/bjc.2014.499